iShares U.S. Pharmaceuticals ETF outperforms despite drug pricing policy risks, up 38% in 12 months.
The iShares U.S. Pharmaceuticals ETF (IHE) has gained 38% over the past year despite threats from U.S. drug pricing policies like the ‘most favored nation’ order. The ETF benefits from dividends and strong drug pipelines, especially from major holdin…